EQUITY RESEARCH MEMO
AlivaMab Biologics
Generated 5/9/2026
Executive Summary
Conviction (model self-assessment)50/100
AlivaMab Biologics is a private contract research organization headquartered in San Diego, founded in 2019. The company specializes in antibody discovery and development using proprietary transgenic mouse platforms and advanced antibody engineering technologies. By partnering with biopharmaceutical firms, AlivaMab aims to accelerate the creation of superior therapeutic antibodies. Its business model is service-based, generating revenue through research collaborations and milestone payments. While the company has no disclosed pipeline or financials, its platform technology positions it as a key enabler in the antibody therapeutics space, with potential for growth through strategic partnerships and platform advancements.
Upcoming Catalysts (preview)
- Q3 2026Major pharma partnership announcement60% success
- 2026Launch of next-generation transgenic mouse platform70% success
- 2027Partner IND filing for an AlivaMab-discovered antibody40% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)